314
Participants
Start Date
October 8, 2008
Primary Completion Date
April 6, 2009
Study Completion Date
April 6, 2009
LDX 30 mg
Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
LDX 50 mg
Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
LDX 70 mg
Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
Placebo
Placebo will be identical to test product.
Bioscience Research, LLC, Mount Kisco
Youth and Family Research Program/WP IC ADHD Research Program, Pittsburgh
CRI Worldwide, Philadelphia
Neuroscience, Inc, Herndon
Dominion Clinical Research, Midlothian
Triangle Neuropsychiatry, PLLC, Durham
Northwest Behavioral Research Center, Marietta
Atlanta Center for Medical Research, Atlanta
Clinical Neuroscience Solutions, Inc., Jacksonville
Sarkis Clinical Trials, Gainesville
Amedica Research Institute, Inc., Hialeah
Miami Research Associates, South Miami
Janus Center for Psychiatric Research, West Palm Beach
Florida Clinical Research Center, LLC, Bradenton
Valerie Arnold, Memphis
Four Rivers Clinical Research, Inc., Paducah
Pedia Research, LLC, Owensboro
University Hospitals of Cleveland Division of Child Adolescent Psychiatry, Cleveland
Clinco Inc., Terre Haute
Bart Sangal, MD, Troy
Innovis Health/Odyssey Research, Fargo
Capstone Clinical Research, Libertyville
Psychiatric Associates, Overland Park
Vince and Associates Clinical Research, Inc., Overland Park
Cientifica, Inc at Prairie View, Newton
Louisiana Research Associates, Inc, New Orleans
Clinical Study Centers, LLC, Little Rock
IPS Research Company, Oklahoma City
Bayou City Research, Ltd, Houston
Red Oak Psychiatry Associates, PA, Houston
ADHD Clinic of San Antonio, San Antonio
FutureSearch Trials, Austin
Center for Psychiatry and Behavioral Medicine, Inc, Las Vegas
Peninsula Research Associates, Inc, Rolling Hills Estates
Psychiatric Centers at San Diego (PCSD-Feighner Research Institute), San Diego
Valley Clinical Research, Inc., El Centro
Elite Clinical Trials, Inc, Wildomar
Summit Research Network, Portland
OCCI Inc, Salem
OCCI, Eugene
Northwest Clinical Research Center, Bellevue
Clinical Neuroscience Solutions, Inc., Orlando
Children's Specialized Hospital, Toms River
Vermont Clinical Study Center, Burlington
Neuropsychiatric Associates, Woodstock
Lead Sponsor
Shire
INDUSTRY